Your browser is no longer supported. Please, upgrade your browser.
XLV Health Care Select Sector SPDR ETF daily Stock Chart
Health Care Select Sector SPDR ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week0.29%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-3.43%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-5.90%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio3.75 Perf Half Y-1.42%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year4.56%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range61.97 - 75.71 Perf YTD-1.29%
Dividend1.07 P/FCF- EPS past 5Y- ROI- 52W High-7.16% Beta-
Dividend %1.52% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low13.43% ATR0.78
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)39.84 Volatility0.80% 0.99%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.84 Prev Close69.96
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume8.18M Price70.29
Recom- SMA20-1.66% SMA50-2.88% SMA2000.45% Volume6,869,927 Change0.47%
Oct-20-16 12:32PM  What To Expect From Stocks Under A Clinton Presidency
10:06AM  Which Factors Might Lead to Stagnant Growth for Soliris in 3Q16?
08:05AM  What Biogen Is Doing that Put It in Good Favor with Analysts
Oct-19-16 07:12AM  An ETF Tax Hustle at Forbes
Oct-18-16 10:45AM  J&J Beats on Q3 Earnings: Should You Buy Healthcare ETFs?
08:12AM  Abbott Labs, St. Jude agree to sell assets for $1.1 billion after merger closes at MarketWatch
Oct-17-16 12:08PM  3 ETFs to Buy if You Think Johnson & Johnson Will Beat Earnings
Oct-15-16 10:01AM  How To Invest If Hillary Clinton Wins The Election at Forbes
12:19AM  [$$] Payouts Will Benefit as Buybacks Lose Favor at
Oct-14-16 04:34PM  How to Protect Yourself From a 15% Correction in the Stock Market
Oct-13-16 04:04PM  Did Pfizers Top Line Growth Beat Its Peers?
07:36AM  Classic investor mistakes to avoid: Pro
Oct-12-16 03:00PM  Biotech under pressure: how to trade it at CNBC
12:10PM  The politics of health care
07:05AM  Markets sag on weak earnings
Oct-11-16 04:04PM  How Will September Jobs Report Affect Feds Rate Hike Decision?
02:12PM  Lakos-Bujas: Superior growth in health care sector
Oct-10-16 03:25PM  Stocks Trying To Break Out Relative To Bonds
Oct-07-16 06:04PM  Bristol-Myers Squibbs Premium Valuation
11:53AM  The only thing investors need to do with the Nasdaq is follow its lead at MarketWatch
Oct-06-16 05:08PM  BofA: This market is 'terrifying'
01:00PM  Top 50 ETFs Over Five Years: Health Care Loses Some Ground at Forbes
08:04AM  Why Do Investment Firms Expect Changes in the Market?
Oct-04-16 11:04AM  Understanding Gilead Sciences NASH Pipeline
11:04AM  Whats the Outlook for Merck & Co.?
11:04AM  Thermo Fisher Scientifics Latest Valuation
Oct-03-16 08:05AM  What Is Zimmer Biomets Latest Valuation?
Oct-01-16 01:48PM  Next Bear Market Could Catch Many Off Guard
Sep-30-16 05:22PM  Q4: What to expect
02:21PM  How Has Baxters Stock Performed?
Sep-29-16 02:04PM  Why Teva and Regeneron Entered Collaboration Agreement
Sep-28-16 08:04AM  Vertex Looks to Improve Its Gross and Net Margins
Sep-27-16 09:55AM  Eli Lilly: This is Gonna Be Good at
08:06AM  Is Kalydeco Positioned Well Enough to Achieve Sustained Growth?
Sep-26-16 02:02PM  Increased Government Spending Can Have a Domino Effect
11:05AM  A Look at Johnson & Johnsons Recent Stock Performance
10:05AM  Inside Johnson & Johnsons Latest US Medical Device Launch
08:06AM  Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
07:23AM  Theres big volatility ahead for this sector: Goldman Sachs at CNBC
06:59AM  Pfizer decides against splitting into two companies at MarketWatch
Sep-22-16 11:04AM  Hows Gilead Sciences Expected to Perform in 2016?
Sep-19-16 05:04PM  Rise in Consumer Price Index Likely to Push Fed Rate Hike
03:00PM  August Jobs Report: Labor Markets Rapidly Changing Composition
11:04AM  St. Jude Medicals Stock Prices Are on a Declining Trend
08:05AM  What Analysts Think about Bristol-Myers Squibb
Sep-16-16 01:30PM  This Advisory Firms Name Held True to Form for St. Jude Medical
Sep-15-16 02:41PM  Stop Wasting Energy On The VIX
12:46PM  Stryker Acquires Ivy Sports Medicine to Strengthen Its Business
11:38AM  The Case for Health Care Stocks (Especially Biotech) at
08:43AM  Price of pharma innovation: Pro
08:41AM  Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial at MarketWatch
06:33AM  Executive Edge: Improving health care
Sep-12-16 02:15PM  Why Is The Fed So Hesitant To Raise Interest Rates?
05:51AM  Where to create alpha amid rising rates: Pro
Sep-09-16 04:28PM  FDA Approves Medtronics Enlite Sensor for iPro2 CGM System
04:19PM  Pfizers Essential Health Business: What You Need to Know
03:04PM  Market Watches to See if Biogen Will Meet Its Raised Guidance
12:37PM  What Are Analysts Recommendations for Perrigo in 2016?
11:04AM  Analysts Look for Celgene to Offer Striking Returns in 2016
08:06AM  Rubenstein Thinks That Healthcare Spending Will Increase in the US
07:34AM  Politic-proofing your portfolio: Pro
Sep-08-16 09:59AM  Why Leon Cooperman Thinks Interest Rate Normalization Is Required
08:04AM  How Can Revlimid Eventually Lead the Lymphoma Space?
Sep-07-16 06:04PM  How Cepheid Fits Strategically into DHRs Portfolio
04:04PM  DHR to Reap $200 Million in Cost Synergies, Revenue through Buy
02:23PM  What Made Cepheid Attractive to Danaher?
08:05AM  Will the August Jobs Report Soften the Feds Rate Hike Urgency?
Sep-02-16 12:30PM  Raymond James: Abbvie has value-enhancing catalysts
08:04AM  An Overview of Pfizers Oncology Business
Sep-01-16 10:04AM  Regenerons Growth Opportunities: Praluent, Sarilumab, and Dupilumab
08:04AM  A Look at Pfizers Innovative Health Business
Aug-31-16 01:22PM  Analysts Recommendations for Edwards Lifesciences in 2016
12:34PM  Analysts Recommendations for C.R. Bard in 2016
10:48AM  Healthcare ETFs Need Some Rest
08:05AM  Johnson & Johnsons Medical Devices Segment
Aug-30-16 06:04PM  How StrataGraft Could Benefit Mallinckrodts Hospital Portfolio
03:04PM  Competition in the Robotics Surgical Space Impacts Intuitive Surgical
02:13PM  America's opioid problem
01:35PM  Surgeon General on opioids, zika and drug costs
09:39AM  Biotech ETFs Back In The Spotlight
07:47AM  Big trader doubles down on health care
Aug-29-16 02:03PM  US health care system needs more transparency: Pro
01:09PM  EpiPen as metaphor for broken health care system: Brill
12:26PM  Healthcare's best bets following generic EpiPen
11:05AM  A Look at Allergans Growth Pharma Model
10:05AM  How Allergan Is Still Benefiting from Actavis Deal
08:05AM  What Investors Should Know about the Pfizer-Anacor Deal
Aug-26-16 08:05AM  Third Point Lowered Its Position in Dow Chemical
Aug-25-16 03:19PM  Janus Capital Increased Position in Microsoft in 2Q16
08:30AM  Mylan stock set to snap four-day losing streak at MarketWatch
Aug-23-16 04:02PM  Best ETFs: Sector Funds at Forbes
03:04PM  How AbbVie Expects Risankizumab to Be a Transformative Therapy
02:00PM  Return Analysis: Health Care Select Sector SPDR (XLV) at Investopedia
12:27PM  An Appealing, Cost-Efficient Healthcare ETF
08:16AM  It Could Be An Interesting Ride For Healthcare ETFs
Aug-22-16 12:01PM  ETFs in Focus on Pfizer's Medivation Acquisition
11:05AM  How Did Bristol-Myers Squibbs Virology Segment Perform?
Aug-18-16 11:04AM  Mylan Expects to Be a Dominant Player in the Respiratory Market
Aug-17-16 03:06PM  Troubled drug company Valeant handed second upgrade of the week at MarketWatch
12:02PM  Brean Downgrades The Healthcare Sector On Technical Indicators
The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.